GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Echo Therapeutics (ECTE) [hlAlert]

Rating:
Buy ECTE
down 96.02 %

Echo Therapeutics (ECTE) rated Buy with price target $5 by Morgan Joseph

Posted on: Friday,  Mar 25, 2011  9:25 AM ET by Morgan Joseph

Morgan Joseph rated Buy Echo Therapeutics (NASDAQ: ECTE) on 03/25/2011, when the stock price was $37.50. Since
then, Echo Therapeutics has lost 96.03% as of 01/26/2016's recent price of $1.49.
If you would have followed this Morgan Joseph's recommendation on ECTE, you would have lost 96.02% of your investment in 1768 days.

Echo Therapeutics, Inc. (Echo) is a medical device and specialty pharmaceutical company. The Company is developing a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system for use in clinical settings and for people with diabetes together with a range of transdermal reformulations of specialty pharmaceutical products approved by the United States Food and Drug Administration (FDA). The Symphony tCGM System is a non-invasive (needle-free), wireless tCGM system designed to provide blood glucose data. Symphony incorporates the feedback mechanism for optimal skin permeation control and the transdermal sensor to detect glucose trends, for controlling complications associated with blood glucose levels that stray outside of a target range. Symphony incorporates the skin permeation, transdermal sensor, wireless transmission and data display technologies. The specialty pharmaceuticals pipeline is based on the AzoneTS transdermal drug reformulation technology.

Morgan Joseph is committed to providing timely, objective and actionable investment advice on the companies and securities we follow. Our team of equity analysts covers a growing universe of stock issues across a broad range of industry sectors. As a middle market-focused firm, our approach is not to publish research on as many companies as possible within a number of industry sectors. Rather, our research analysts distinguish themselves by zeroing in on quality companies with growth prospects or which present special situations. These companies often lack a research following. This enables our analysts to provide insight to investors in companies that are not well understood nor fairly valued.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/25/2011 9:25 AM Buy
None
37.50 50.00
as of 12/30/2011
1 Week down  -0.44 %
1 Month down  -9.60 %
3 Months down  -22.06 %
1 YTD down  -39.73 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy